Ann: FDA grants broader orphan drug status to PTX100 for TCLs, page-37

Its a funny workd mate.

The good news is the FDA have stated getting drugs to patients with unmet needs as quickly as possible is important.

I have been overweight (oi! not like that!) in PTX for a long time. That last announcement has me adding more. It is one of the more bullish announcements PTX has made.

We had good results from the basket study of PTX100. They have concentrated the extension trial on the indication that responded the most. We should get an idea of how that is going soon. We have protection for our Kras drug now in multiple diseases from the FDA. More than we asked for!

This market cap is crazy just considering the above. Omnicar, and PTX200 also arent factored in.

Opportunity for those who are in a position to buy or hold. Frustrating for those who need to sell.